Zevra Therapeutics 2024年第二季度GAAP每股收益$（0.48）错过$（0.44）估计，销售额为444.9万美元，超过441.2万美元估计

Zevra Therapeutics (NASDAQ: ZVRA) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.44) by 9.09 percent. This is a 500 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $4.449 million which beat the analyst consensus estimate of $4.412 million by 0.85 percent. This is a 47.47 percent decrease over sales of $8.470 million the same period last year.